Semaglutide

Description

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the incretin hormone GLP-1, which is naturally secreted from the gut in response to food intake. Structurally, Semaglutide is an acylated analog of human GLP-1 with modifications at positions 8 and 34, and an attached C-18 fatty acid chain that enables albumin binding and extends its half-life significantly. It has been extensively studied in clinical research for its effects on glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and central appetite regulation. Semaglutide activates GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, making it a versatile research tool for studying metabolic signaling pathways. The peptide has been investigated in numerous clinical trials for metabolic and cardiovascular research. Supplied as a lyophilized powder. For research use only.